HRT Financial’s Revolution Medicines RVMD Stock Holding History

HRT Financial’s Portfolio RVMD Stock Details RVMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$7.71M	Buy	+79,300	New	+$8.01M	0.02%	739

Other funds holding RVMD

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

HRT Financial's RVMD Position: Q1 2026 in Review

HRT Financial sold out of Revolution Medicines (RVMD) in Q1 2026, closing a stake of 11,192 shares — an estimated $1.13M sold.

HRT Financial first reported a position in RVMD in Q4 2021 and held it in 9 quarters. The position peaked at $25.3M in Q2 2025. 512 funds tracked by Wall St. Rank hold RVMD as of Q1 2026.

HRT Financial reported no remaining Revolution Medicines position as of Q1 2026 after selling out during the quarter.
HRT Financial sold 11,192 Revolution Medicines shares in Q1 2026, an estimated $1.13M.
HRT Financial first reported a position in Revolution Medicines in Q4 2021 and held it in 9 quarters.
HRT Financial's Revolution Medicines position peaked at $25.3M in Q2 2025.
512 funds tracked by Wall St. Rank held Revolution Medicines as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.